Drugs / Botulinum toxin B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00384579 | Feb 2008 → Aug 2010 | — | United States Department of Defense | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT03103074 | Jun 2017 → Mar 2018 | hidradenitis suppurativa | University Hospital of North Norway | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulinum toxin B | “Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000...” NCT03103074 ↗ |
| Route | Intramuscular | “Botulinum Toxin B (Myobloc®) injected into the lumbar paravertebral muscles” NCT00384579 ↗ |